Desktop Health announces first patients treated CMFlex, an off-the-shelf 3D-printed synthetic bone graft product

Desktop Health, the trusted production-grade medical 3D printing brand of Desktop Metal, today announced the first patients have been treated with CMFlex, an off-the-shelf 3D printed synthetic bone graft product developed and manufactured by Chicago-based Dimension Inx on the 3D-Bioplotter.

CMFlex
Dr Adam Jakus (left) and Dr Ramille Shah (right) have been developing the material and product since 2009 on the Desktop Health 3D-Bioplotter (Image: Business Wire)

“These first cases are not only indicative of a new generation of biomaterials, but also highlight our technology platform’s unique capability to rapidly create biomaterials that direct cell behaviour to restore tissue and organ function. It is a proud moment for us to be able to demonstrate the value of therapeutics derived from integrating novel biomaterial design and 3D-printing approaches,” said Dr Adam Jakus, CTO, head of technology strategy, and Dimension Inx co-founder.

Dimension Inx received FDA clearance of CMFlex in December of 2022. CMFlex is currently available to a limited number of key surgeons with a broader release to follow later in 2024.

The first jaw cases were performed by Dr Derek Steinbacher, director of West River Surgery Center, former professor plastic surgery and chief of oral and maxillofacial surgery at Yale New Haven Health, and Dr Brian Farrell, DDS, MD, of the Carolinas Center for Oral & Facial Surgery. Procedures performed included a mandibular angle augmentation, surgery of the lower jaw, and maxillary segmental osteotomy, surgery of the upper jaw.

CMFlex has also been used in dental socket preservation surgeries for future dental implant placement by Dr Robert Bosack, DDS, Oral, Maxillofacial & Dental Implant Surgery.

CMFlex
CMFlex has an intentionally engineered three-dimensional architecture with macro, micro, and nano level features designed to promote bone regeneration after implantation to promote healing. CMFlex is comprised of hydroxyapatite, a naturally occurring mineral found in bone, combined with biodegradable polylactide-co-glycolide (PLG) polymer. (Image: Business Wire)

“We are excited by the interest we have already received from surgeons who recognise the importance of a ready-to-use solution with great handling characteristics and the ability to cut and shape the graft to match the defect site,” said Dr Ramille Shah, CSO, Head of R&D, and co-founder of Dimension Inx.

Founded in 2017, Dimension Inx is a regenerative therapeutics company that designs, develops, and manufactures therapeutic products to restore tissue and organ function. The company owns four Desktop Health 3D-Bioplotters – two used for R&D and two used for manufacturing their commercial CMFlex product.

Dimension Inx received FDA clearance of CMFlex in December of 2022. CMFlex is currently available to a limited number of key surgeons with a broader release to follow later in 2024.

Related: RUNYES AMERICA introduced at the 2023 Greater New York Dental Meeting as joint venture between Denterprise International and RUNYES